Keeping Track: Iovance’s Amtagvi Approval Brings T Cell Therapy To Solid Tumors
Melanoma treatment Amtagvi is US FDA’s biologics center’s first novel approval of 2024.
Melanoma treatment Amtagvi is US FDA’s biologics center’s first novel approval of 2024.